Biotech Runners: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

VIVUS Inc. (NASDAQ:VVUS) stock was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating. They now have a $8.00 price target on the stock, down previously from $15.00. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 1.00% in last session and finished the day at $6.09. Traded volume was 5,364,675 million shares in the last session and the average volume … Continue reading Biotech Runners: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Rexahn Pharmaceuticals (NYSEMKT:RNN), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -3.34% in last session and finished the day at $8.69. Traded volume was 1,200.00 shares in the last session and the average volume of the stock remained 26.48 million shares. The beta of the stock remained 1.64. Ariad Pharmaceuticals, Inc. … Continue reading Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Rexahn Pharmaceuticals (NYSEMKT:RNN), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Healthcare ACtive Stocks: MannKind (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Bristol-Myers Squibb Co (NYSE:BMY)

MannKind Corporation (NASDAQ: MNKD) is a small company based in Valencia, California, poised to launch its FDA approved drug, Afrezza, as treatment indications for both Type 1 and Type 2 diabetes. Despite near unanimous backing from experts at the Advisory Committee (ADCOM) and the medical community, Mr. Market is still pessimistic on the company.  MannKind Corporation (NASDAQ:MNKD) stock performance was -2.50% in last session and finished the … Continue reading Healthcare ACtive Stocks: MannKind (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Bristol-Myers Squibb Co (NYSE:BMY)

Trending Stocks – Priceline (NASDAQ:PCLN) , Ariad Pharmaceuticals (NASDAQ:ARIA) , Hi-Crush Partners (NYSE:HCLP) , Rackspace (NYSE:RAX) , SMFG)

Priceline Group Inc (NASDAQ:PCLN) Director Jeffery H. Boyd sold 3,000 shares of Priceline Group stock on the open market in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $1,228.00, for a total transaction of $3,684,000.00. Following the sale, the director now directly owns 194,125 shares of the company’s stock, valued at approximately $238,385,500. Priceline Group Inc (NASDAQ:PCLN) stock … Continue reading Trending Stocks – Priceline (NASDAQ:PCLN) , Ariad Pharmaceuticals (NASDAQ:ARIA) , Hi-Crush Partners (NYSE:HCLP) , Rackspace (NYSE:RAX) , SMFG)

Health Stocks to Watch: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Eli Lilly (NYSE:LLY)

Earlier this month, Vivus Inc. (NASDAQ:VVUS) said it filed a patent-infringement lawsuit against Actavis PLC ( ACT ) alleging that the drug maker’s planned generic version of weight-loss drug Qsymia infringes its patents. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 3.97% in last session and finished the day at $5.50. Traded volume was 4.47million shares in the last session and the average volume of the stock remained 3.04million … Continue reading Health Stocks to Watch: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Eli Lilly (NYSE:LLY)

Hot Biotech Movers: Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), Insmed Incorporated (NASDAQ:INSM), Gilead Sciences, Inc. (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) saw a significant decrease in short interest during the month of May. As of May 30th, there was short interest totalling 8,284,614 shares, a decrease of 15.5% from the May 15th total of 9,799,100 shares. Several analysts have recently commented on the stock. Analysts at Roth Capital downgraded shares of Chelsea Therapeutics International from a “buy” rating to a “neutral” … Continue reading Hot Biotech Movers: Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), Insmed Incorporated (NASDAQ:INSM), Gilead Sciences, Inc. (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)